Tiago Fauth
Stock Analyst at Wells Fargo
(1.24)
# 3,426
Out of 4,734 analysts
130
Total ratings
31.68%
Success rate
-12.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INZY Inozyme Pharma | Maintains: Overweight | $14 → $11 | $1.36 | +708.82% | 2 | Jan 13, 2025 | |
| VRNA Verona Pharma | Maintains: Overweight | $64 → $74 | $51.89 | +42.61% | 3 | Jan 8, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $75 → $88 | $40.00 | +120.00% | 7 | Dec 20, 2024 | |
| SVRA Savara | Initiates: Overweight | $8 | $2.93 | +173.04% | 1 | Dec 20, 2024 | |
| MNKD MannKind | Initiates: Overweight | $9 | $6.01 | +49.75% | 1 | Dec 20, 2024 | |
| KROS Keros Therapeutics | Maintains: Overweight | $88 → $111 | $10.86 | +922.10% | 2 | Dec 11, 2024 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $56 → $68 | $43.84 | +55.11% | 1 | Nov 26, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Overweight | $55 → $79 | $40.90 | +93.15% | 2 | Nov 12, 2024 | |
| WVE Wave Life Sciences | Maintains: Overweight | $11 → $22 | $10.99 | +100.18% | 2 | Oct 16, 2024 | |
| IRON Disc Medicine | Initiates: Overweight | $75 | $58.25 | +28.77% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $380 | $358.93 | +5.87% | 4 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $207 → $233 | $246.27 | -5.39% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $35 → $2 | $2.58 | -22.48% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $77 | $72.51 | +6.19% | 2 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $2.02 | +2,969.31% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $128.13 | -30.54% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $18.13 | +181.30% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $61.53 | +95.03% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $120 | $3.61 | +3,224.10% | 6 | May 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $23.86 | -83.24% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.90 | +382.76% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $0.36 | +996.49% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $7.26 | +258.13% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $2.97 | +842.76% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $29.94 | +170.59% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.49 | +1,522.72% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.50 | +833.33% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.74 | +1,854.02% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $5.13 | +2,824.55% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $36.20 | -19.89% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $3.21 | +304.98% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $1.22 | +965.57% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $2.54 | -21.26% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $640.52 | -46.92% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $272.11 | -4.82% | 1 | Apr 28, 2021 |
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $14 → $11
Current: $1.36
Upside: +708.82%
Verona Pharma
Jan 8, 2025
Maintains: Overweight
Price Target: $64 → $74
Current: $51.89
Upside: +42.61%
Ultragenyx Pharmaceutical
Dec 20, 2024
Maintains: Overweight
Price Target: $75 → $88
Current: $40.00
Upside: +120.00%
Savara
Dec 20, 2024
Initiates: Overweight
Price Target: $8
Current: $2.93
Upside: +173.04%
MannKind
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $6.01
Upside: +49.75%
Keros Therapeutics
Dec 11, 2024
Maintains: Overweight
Price Target: $88 → $111
Current: $10.86
Upside: +922.10%
PTC Therapeutics
Nov 26, 2024
Maintains: Overweight
Price Target: $56 → $68
Current: $43.84
Upside: +55.11%
Tectonic Therapeutic
Nov 12, 2024
Maintains: Overweight
Price Target: $55 → $79
Current: $40.90
Upside: +93.15%
Wave Life Sciences
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $10.99
Upside: +100.18%
Disc Medicine
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $58.25
Upside: +28.77%
Aug 20, 2024
Maintains: Overweight
Price Target: $350 → $380
Current: $358.93
Upside: +5.87%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $207 → $233
Current: $246.27
Upside: -5.39%
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $35 → $2
Current: $2.58
Upside: -22.48%
May 29, 2024
Maintains: Overweight
Price Target: $55 → $77
Current: $72.51
Upside: +6.19%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $2.02
Upside: +2,969.31%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $128.13
Upside: -30.54%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $18.13
Upside: +181.30%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $61.53
Upside: +95.03%
May 26, 2023
Reiterates: Outperform
Price Target: $120
Current: $3.61
Upside: +3,224.10%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $23.86
Upside: -83.24%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.90
Upside: +382.76%
May 16, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.36
Upside: +996.49%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $7.26
Upside: +258.13%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $2.97
Upside: +842.76%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $29.94
Upside: +170.59%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.49
Upside: +1,522.72%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.50
Upside: +833.33%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.74
Upside: +1,854.02%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $5.13
Upside: +2,824.55%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $36.20
Upside: -19.89%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $3.21
Upside: +304.98%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $1.22
Upside: +965.57%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $2.54
Upside: -21.26%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $640.52
Upside: -46.92%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $272.11
Upside: -4.82%